Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Products under Development by Stage of Development | 7 | 1 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Products under Development by Therapy Area | 8 | 1 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Products under Development by Indication | 9 | 2 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Products under Development by Companies | 13 | 2 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Therapeutics Assessment | 15 | 7 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Companies Involved in Therapeutics Development | 22 | 3 |
| Arno Therapeutics, Inc. | 22 | 1 |
| Intezyne, Inc | 23 | 1 |
| Nuevolution AB | 24 | 1 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Drug Profiles | 25 | 10 |
| AR-12 Drug Profile | 25 | 3 |
| IT-139 Drug Profile | 28 | 2 |
| NEO-100 Drug Profile | 30 | 2 |
| Rasolvir Drug Profile | 32 | 1 |
| Recombinant Peptide to Target TPI-1 and GRP-78 for Oncology Drug Profile | 33 | 1 |
| Small Molecule to Inhibit GRP78 for Oncology Drug Profile | 34 | 1 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Dormant Projects | 35 | 1 |
| 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Featured News &Press Releases | 36 | 14 |
| May 13, 2016: NeOnc Technologies Announces Initiation of Phase 1/2a Clinical Trial of NEO100 in Recurrent Glioblastoma Multiforme (GBM) | 36 | 1 |
| Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis | 36 | 2 |
| Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains | 38 | 1 |
| Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference | 39 | 1 |
| Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs | 40 | 1 |
| Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition | 41 | 1 |
| Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 | 42 | 1 |
| May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research | 43 | 1 |
| May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 | 44 | 1 |
| Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases | 45 | 1 |
| May 24, 2012: Niiki Pharma To Present Final Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012 | 45 | 1 |
| Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer | 46 | 1 |
| Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339 | 46 | 1 |
| Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent, NKP-1339 | 47 | 1 |
| Nov 15, 2011: Niiki Pharma Reports On Synergistic Activity Of New Anti-Cancer Agent NKP-1339 With Other Anti-Cancer Agents | 48 | 2 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |